Clinical Trial Update: Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating lapatinib in combination with paclitaxel for ovarian cancer; safety and tolerability results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Tykerb (lapatinib)

Snippet

Sponsor: Frederick R. Ueland, M.D. | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-06-29